FLGT
Fulgent Genetics, Inc.Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Upcoming events
| Date | Event | Type |
|---|---|---|
| 2026-07-30 20:30 UTC | Q2 2026 Fulgent Genetics Earnings Conference Call | Earnings call |
Recent news
| Date | Headline |
|---|---|
| 2026-07-09 |
Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
EL MONTE, Calif. --(BUSINESS WIRE)--Jul. 9, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2026 |
| 2026-06-01 |
Fulgent Presents Updated FID-007 Data at ASCO 2026
EL MONTE, Calif. --(BUSINESS WIRE)--Jun. 1, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track |
| 2026-05-21 |
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
EL MONTE, Calif. --(BUSINESS WIRE)--May 21, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its full abstract has been released on |
| 2026-05-01 |
Fulgent Reports First Quarter 2026 Financial Results
Reiterates revenue guidance for fiscal year 2026 Executed on stock repurchase program; purchased approximately 2.6 million shares in the first quarter of 2026 using $40.1 million in cash Revenue of $71.1 million GAAP gross profit of $21.5 million, or GAAP gross margin of 30.2%; Non-GAAP gross |
| 2026-04-22 |
Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting
EL MONTE, Calif. --(BUSINESS WIRE)--Apr. 22, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its abstract was selected to be |
| 2026-04-16 |
Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026
EL MONTE, Calif. --(BUSINESS WIRE)--Apr. 16, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2026 |
| 2026-03-17 |
Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx
EL MONTE, Calif. --(BUSINESS WIRE)--Mar. 17, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced the completion of the acquisition of Bako Diagnostics, a |
| 2026-02-27 |
Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results
Revenue of $83.3 million, growing 9% year-over-year GAAP gross profit of $32.6 million, or GAAP gross margin of 39.1%; Non-GAAP gross profit of $34.2 million, or Non-GAAP gross margin of 41.0% GAAP loss of $23.4 million, or ( $0.76) per share; Non-GAAP income of $5.2 million, or $0.16 per share |
| 2026-02-12 |
Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026
EL MONTE, Calif. --(BUSINESS WIRE)--Feb. 12, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its fourth quarter and |
| 2025-12-22 |
Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx
Proposed acquisition will add new anatomic pathology services, proprietary PCR tests and a national client base EL MONTE, Calif. --(BUSINESS WIRE)--Dec. 22, 2025-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and |
| 2025-11-07 |
Fulgent to Participate in Upcoming Conferences
EL MONTE, Calif. --(BUSINESS WIRE)--Nov. 7, 2025-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that members of its management team are |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-05-01 | Q1 2026 Fulgent Genetics Earnings Conference Call | Earnings call |
| 2026-02-27 | Q4 2025 Fulgent Genetics Earnings Conference Call | Earnings call |
| 2025-12-02 | Piper Sandler 37th Annual Healthcare Conference | Conference |
| 2025-11-10 | 2025 UBS Global Healthcare Conference | Conference |
| 2025-11-07 | Q3 2025 Fulgent Genetics Earnings Conference Call | Earnings call |
| 2025-08-01 | Q2 2025 Fulgent Genetics Earnings Conference Call | Earnings call |
| 2025-05-02 | Q1 2025 Fulgent Genetics Earnings Conference Call | Earnings call |
| 2025-02-28 | Q4 2024 Fulgent Genetics Earnings Conference Call | Earnings call |
| 2024-12-04 | Piper Sandler 36th Annual Healthcare Conference | Conference |
| 2024-11-12 | UBS Global Healthcare Conference | Conference |
Source: https://ir.fulgentgenetics.com/